Aerie Pharmaceuticals Inc. (AERI)

18.79
0.09 0.48
NASDAQ : Health Technology
Prev Close 18.88
Open 18.78
Day Low/High 18.40 / 19.27
52 Wk Low/High 17.51 / 50.10
Volume 550.66K
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 46.32M
Market Cap 882.41M
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Aerie Pharmaceuticals Announces Appointment Of Judith J. Robertson As Chief Commercial Officer

Aerie Pharmaceuticals Announces Appointment Of Judith J. Robertson As Chief Commercial Officer

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Apple, Alphabet, Starbucks: Doug Kass' Views

Apple, Alphabet, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on divergences in the market's armor and observes that real tech regulation is complicated.

Aerie Pharmaceuticals Completes Enrollment Of Mercury 2 Phase 3 Registration Trial Of Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%

Aerie Pharmaceuticals Completes Enrollment Of Mercury 2 Phase 3 Registration Trial Of Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient...

Aerie Pharmaceuticals To Participate In Two Investor Conferences In December

Aerie Pharmaceuticals To Participate In Two Investor Conferences In December

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management...

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Facebook, Home Depot, Disney: Doug Kass' Views

Facebook, Home Depot, Disney: Doug Kass' Views

Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.

4 Stocks You Should Watch Because They're Breaking Out Higher

4 Stocks You Should Watch Because They're Breaking Out Higher

These four stocks are breaking out on strong technicals: Aerie Pharmaceuticals (AERI), Finisar (FNSR), Tower Semiconductor (TSEM), and Vuzix (VUZI).

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

Aerie Pharmaceuticals To Participate In Three Investor Conferences In November

Aerie Pharmaceuticals To Participate In Three Investor Conferences In November

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management...

Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Business Update

Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals To Announce Third Quarter 2016 Financial Results And Host Conference Call On Wednesday, November 2, 2016

Aerie Pharmaceuticals To Announce Third Quarter 2016 Financial Results And Host Conference Call On Wednesday, November 2, 2016

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the "Company"), announced today that its third quarter 2016 financial results will be released after the market closes on Wednesday, November 2, 2016.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views

J.C.Penney, Wells Fargo, Deutsche Bank: Doug Kass' Views

Doug Kass shares his thoughts on the banks and looks back on 20 years with TheStreet.

Aerie Pharmaceuticals To Host Investor Day On October 5, 2016

Aerie Pharmaceuticals To Host Investor Day On October 5, 2016

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.

Cloudy Outlook for Aerie Pharma's Glaucoma Drug

Cloudy Outlook for Aerie Pharma's Glaucoma Drug

When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.

Wells Fargo, Citigroup, Apple: Doug Kass' Views

Wells Fargo, Citigroup, Apple: Doug Kass' Views

Doug Kass shares his thoughts on Wells Fargo and Warren Buffett.

Notable Friday Option Activity: AERI, AWH, WATT

Notable Friday Option Activity: AERI, AWH, WATT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Aerie Pharmaceuticals Inc , where a total of 9,538 contracts have traded so far, representing approximately 953,800 underlying shares. That amounts to about 72.9% of AERI's average daily trading volume over the past month of 1.3 million shares.

Aerie Pharmaceuticals Raises $125 Million In Public Offerings

Aerie Pharmaceuticals Raises $125 Million In Public Offerings

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Public Offering Of Common Stock

Aerie Pharmaceuticals Announces Public Offering Of Common Stock

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Trending Tickers: AAPL, TMUS, FIT, AERI

Trending Tickers: AAPL, TMUS, FIT, AERI

Apple continues to benefit from strong iPhone sales, but telecom carriers like T-Mobile are also benefiting.

Bought Aerie Earlier? Congratulations

Bought Aerie Earlier? Congratulations

An update on some recent small biotech recommendations.

Why Shares of Aerie Pharmaceuticals (AERI) are Soaring Today

Why Shares of Aerie Pharmaceuticals (AERI) are Soaring Today

Shares of Aerie Pharmaceuticals (AERI) were gaining north of 50% during early-morning trading on Thursday, as the company's glaucoma drug met a key phase three study endpoint.

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Fear of Being Left Out Is Lifting Indices

Fear of Being Left Out Is Lifting Indices

The overall technical condition of the indices remains negative.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

Aerie Pharmaceuticals Submits New Drug Application To U.S. Food And Drug Administration For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals Submits New Drug Application To U.S. Food And Drug Administration For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

TheStreet Quant Rating: D- (Sell)